Venus Remedies has surged 6.3% to Rs 291 after the company said it has received patent from Mexico for its novel antibiotic product Potentox.
Granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of Potentox, Venus Remedies said in a statement.
The patent provides an exclusivity period for Potentox up to 2025. The drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine, it said.
Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes, it said.
The stock opened at Rs 279 and touched high of Rs 299 on BSE. A combined around 175,000 shares have changed hands on the counter so far on BSE and NSE.
Granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of Potentox, Venus Remedies said in a statement.
The patent provides an exclusivity period for Potentox up to 2025. The drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine, it said.
Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes, it said.
The stock opened at Rs 279 and touched high of Rs 299 on BSE. A combined around 175,000 shares have changed hands on the counter so far on BSE and NSE.
